Canadian Province Expands Biosimilar Switching, But Patient Group Voices Concerns
British Columbia’s move to switch gastrointestinal patients to biosimilar infliximabs by March 2020 has pleased local industry but upset an originator-backed patients’ group.
You may also be interested in...
Ontario has joined several other Canadian provinces and territories by implementing a biosimilar switching policy for Ontarians taking biologic drugs.
Citizens enrolled on Nova Scotia’s Pharmacare programs have 12 months to switch to biosimilar versions of certain biologic drugs, including some insulins and medications used to treat Crohn’s disease and rheumatoid arthritis.
Biosimilars Canada president Jim Keon has urged the province of Ontario to follow other Canadian provinces by adopting a biosimilar switching policy for its public drug program, in order to cut costs on biologics and re-invest in the healthcare system.